AzTrials
AzTrials

Osteoarthritis, KneeNCT04234412

Treatment of Osteoarthritic Knee With High Tibial Osteotomy and Implantation of Allogenic Human Umbilical Cord Blood-derived Stem Cells.

A study testing umbilical cord blood stem cell implantation for osteoarthritis treatment in people with Osteoarthritis, Knee, run by Uijeongbu St. Mary Hospital.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The purpose of this study is to evaluate the clinical results after implantation of human umbilical cord blood-derived mesenchymal stem cells(hUCB-MSCs) and High tibia osteotomy in patients with medial compartment osteoarthritis(MCOA) as well as varus deformity of the knee joint. Read more about this study

Who is it for?
Ages 30 to 65 years
Conditions the study is for
Osteoarthritis, Knee
What is being tested?
umbilical cord blood stem cell implantation for osteoarthritis treatment
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
10 participants
Where
No sites listed yet
Study dates
1 Feb 2020to 30 Nov 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • age older than 30 years,
  • full-thickness cartilage lesion measuring at least 2 cm2,
  • femoro-tibial angle (varus or valgus) 5°< in the mechanical axis

Who cannot join

  • ligament injuries (such as injuries of the anterior cruciate ligament and posterior cruciate ligament),
  • metabolic arthritis
  • infectious condition
  • psychosis
  • serious medical illness
  • pregnancy

About this study

The purpose of this study is to evaluate the clinical results after implantation of human umbilical cord blood-derived mesenchymal stem cells(hUCB-MSCs) and High tibia osteotomy in patients with medial compartment osteoarthritis(MCOA) as well as varus deformity of the knee joint.

This study will prospectively evaluate 10 knees after hUCB-MSCs implantation and High Tibial Osteotomy(HTO) in the medial compartment osteoarthritis and varus deformity of the knee joint.

Clinical outcomes will be evaluated using the International Knee Documentation committee(IKDC), Visual analogue scale(VAS), Western Ontario and McMaster Universities Arthritis Index(WOMAC), and patients satisfaction with the surgery.

Being tested
umbilical cord blood stem cell implantation for osteoarthritis treatment
Keywords
osteoarthritis, knee, high tibial osteotomy, umbilical cord blood stem cell, cartilage regeneration
Medical subject headings
Osteoarthritis, Knee, Osteoarthritis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • umbilical cord blood stem cell implantation for osteoarthritis treatmentProcedure or surgery

    The arthroscopic procedure is performed in the supine position after spinal anesthesia. Once the chondral lesion is identified through a standard anteromedial and lateral portal, meniscectomy, meniscal repair, and lateral retinacular release are performed if necessary. microfracture is performed using a microfracture awl.

    Once both the unstable cartilage and subchondral bone are removed in the lesion area and the sclerotic bone is peeled slightly by using a burr, hole(s) are created for implantation by using a drill bit(diameter 4; depth: 4mm). After implantation is performed in the hole by injecting the mixture of sodium hyaluronate and hUCB-MSCs, it is trimmed to the height of the surrounding articular surface.

Study groups in NCT04234412
Study groupRoleWhat they receive
Osteoarthritic knee patientsExperimentalOsteoarthritic Knee of the patients who will be treated wth high tibial osteotomy and implantation of allogenic human umbilical cord blood-derived stem cells.
Receives: Procedure: umbilical cord blood stem cell implantation for osteoarthritis treatment

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. International Cartilage Repair Society (ICRS) grade improvement

    over grade 1 should be improved

    Measured: at 24, 48, 96 weeks after surgery, score changes will be observed.

Secondary outcomes (3)
  1. Visual analogue scale (VAS)

    0-10 score range, lower the better

    Measured: at 24, 48, 96 weeks after surgery, score changes will be observed.

  2. Western Ontario and McMaster Universities Arthritis Index (WOMAC)

    0-100 score range, lower the better

    Measured: at 24, 48, 96 weeks after surgery, score changes will be observed.

  3. International Knee Documentation Committee (IKDC score)

    0-100 % range, lower the better

    Measured: at 24, 48, 96 weeks after surgery, score changes will be observed.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Jan 2020
  2. Study start1 Feb 2020 (estimated)
  3. Primary completion30 Nov 2022 (estimated)
  4. Study completion30 Nov 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
10 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04234412
Sponsor's protocol ID
UC19OISI0134
Status last verified
Jan 2020
First submitted
5 Jan 2020
Last updated
21 Jan 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: according to patient agreement, this is flexible.

Publications

  • Bae BS, Jung JW, Jo GO, Kim SA, Go EJ, Cho ML, Shetty AA, Kim SJ. Treatment of osteoarthritic knee with high tibial osteotomy and allogeneic human umbilical cord blood-derived mesenchymal stem cells combined with hyaluronate hydrogel composite. Stem Cell Res Ther. 2025 Apr 28;16(1):211. doi: 10.1186/s13287-025-04356-9.

    PubMed 40296133

Questions about this trial

What is this clinical trial studying?

A study testing umbilical cord blood stem cell implantation for osteoarthritis treatment in people with Osteoarthritis, Knee, run by Uijeongbu St. Mary Hospital.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 21 Jan 2020. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

International Cartilage Repair Society (ICRS) grade improvement (time frame: at 24, 48, 96 weeks after surgery, score changes will be observed.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04234412, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jan 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in